Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

About Xeris Biopharma Holdings Inc. Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has ...

The average one-year price target for Xeris Biopharma Holdings (NasdaqGS:XERS) has been revised to $11.73 / share. This is an increase of 27.78% from the prior estimate of $9.18 dated November 7, 2025 ...

Xeris Biopharma Holdings, Inc. misses on earnings expectations. Reported EPS is $0.0035 EPS, expectations were $0.01. Operator: Hello, everyone, and thank you for joining us today for the Xeris ...

Full year 2025 total revenue guidance was raised to $285 million to $290 million, up from the prior range of $280 million to $290 million. Pieper explained, "We are raising the low end of our previous ...

Hello, everyone, and thank you for joining us today for the Xeris Biopharma Q3 2025 Earnings Conference Call. My name is Sami, and I'll be coordinating your call today. [Operator Instructions] I'd now ...

Total product revenue-- $74.1 million net product revenue for Q3 2025, increasing 40% year over year, driven by growth across all three products. Recorlev net revenue-- $37 million net revenue for ...

Updating full-year 2025 total revenue guidance to $285-$290 million; previously $280-$290 million Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), ...